ERBB2 and breast carcinoma: Prosigna PAM-50 was prognostic for the local recurrence in post-menopausal ER-positive, HER2-negative breast cancer patients (n = 1204) treated with BCS and randomised between different adjuvant endocrine therapies in the ABCSG-8 trial.